Actor Jo Martin portrays plays British tour guide Ruth Clayton who just so happens to have a time-bending secret.
Here are the five best burns delivered by social-media hotdoggers.
It looks like one of our very favorite infotainment systems is poised to get even better.
French startup ManoMano is raising another mega round of funding. The company operates an e-commerce website for DIY, home improvement and gardening products. This time, ManoMano is raising $139 million (€125 million) with Temasek leading the round.
General Atlantic, Eurazeo, Piton Capital, Bpifrance and Kismet Holdings are also participating. The company announced another significant funding round back in April 2019. At the time, ManoMano raised $125 million (€110 million). Overall, ManoMano has raised $344 million (€310 million) over the past six years.
In 2019 alone, the company grew by 50% with $666 million (€600 million) in gross merchandise value. While the company is still mostly active in France, its other markets (Spain, Italy, Germany and the U.K.) now represent a third of sales figures.
ManoMano is betting on three different pillars to differentiate its e-commerce platform from other, more generalist platforms. First, the company works directly with third-party retailers and take care of logistics as part of the Mano Fulfillment service. Given that the marketplace focuses on a niche, ManoMano could beat competitors who also have a fulfillment service.
Second, ManoMano has built a community of experts and enthusiasts to recreate the experience you’d get when you go to a store. At any time, you can start a conversation with Manodvisors. In 2019, customers had 1 million conversations with Manodvisors. Anybody can become a certified expert and get some revenue from the startup.
Third, ManoMano wants to expand beyond hobbyists with ManoMano Pro. While this service is just getting started, it already represents 10% of the company’s sales in France. Obviously, professionals could lead to a higher average basket size.
With today’s funding round, the company plans to recruit 200 people in Barcelona and Bordeaux.
“I want to build a business which profiles every single researcher and healthcare professional in the world and I want to sell it to industry,” says Ariel Katz, the co-founder and chief executive of H1 Insights.
With the healthcare industry on a mission to digitize and analyze every conceivable data point it can to wring more efficiencies out of its incredibly fragmented and broken system, for Katz, there’s no opportunity that seems more obvious than giving the industry data on its own professionals.
The idea may sound like nothing more than creating a LinkedIn for healthcare professionals, but building an accurate account of the professional ecosystem could be a huge help to businesses as diverse as pharmaceutical companies, hospitals, insurers and, eventually, consumers.
For Katz, it’s the continuation of a longstanding mission to create transparency for data sets that were previously opaque. Katz sold his first company, Research Connection (which became LabSpot), three years ago. That company was designed to uncover the research underway at universities around the country so students could see where they should apply for undergraduate and graduate studies.
After the sale, the young entrepreneur went on a vacation to India, and it was there that he met his co-founder Ian Sax. “He backpacked there to follow his wife who was volunteering with Mother Theresa [and] ended up starting a staffing company.”
The two men became friends and collaborated on projects — including software that would help medical school students find jobs.
Conversations between the two soon hit upon the lack of transparency around what research was happening at which universities and which clinical trials were underway at which hospitals. A visible network of experts, the two men thought, would go a long way toward solving a number of the healthcare industry’s seemingly intractable problems.
“Pharma, biotech and medical devices spend $30 billion per year partnering with researchers and hospitals,” says Katz. “If you could allow a user sitting on the pharmaceutical side to sort and search and rank and analyze researchers… it would help reduce the cost and solve the problem.”
While Katz says the transparency can help solve a number of healthcare’s drug development and discovery problems, he’s wary about creating others. H1 Insights has built certain rules on how its database should be used, which Katz hopes will limit abuse.
“We don’t sell to sales and marketing arms at pharmaceutical companies,” he says. The risk there is that these sales and marketing arms could put undue pressure on doctors to skew research.
The data that H1 collects is already public, so there’s no need for the company to use user-generated data to build out its data set. “It’s all public. The biggest problem is de-duping it,” says Katz.
The company already has 350,000 academic researchers and 4 million healthcare professionals in its database already.
That body of knowledge was enough to attract Y Combinator, which accepted H1 Insight into its latest cohort of companies.
With the accelerator’s help, H1 Insights wants to take its business global and develop applications for the pharmaceutical industry, care providers and ultimately consumers.
The initial application for all of that data is clinical trials.
“The number one reason why clinical trials fail is recruitment,” says Katz. “If you can find a principal investigator who has done a successful clinical trial in an adjacent space,” pharma companies can improve their chances for success, according to Katz.
The helicopter was flying under “special visual flight rules” that allow pilots to fly through low-visibility conditions.
The new coronavirus emerged in China and has since sickened thousands and been identified in the US and Europe.